Drug-Induced Lung Injury PDF
Preview Drug-Induced Lung Injury
Respiratory Disease Series: Diagnostic Tools and Disease Managements Masayuki Hanaoka Hiroyuki Nakamura Kazutetsu Aoshiba Editors Drug-Induced Lung Injury Respiratory Disease Series: Diagnostic Tools and Disease Managements Series Editors Hiroyuki Nakamura Ibaraki Medical Center Tokyo Medical University Ibaraki, Japan Kazutetsu Aoshiba Ibaraki Medical Center Tokyo Medical University Ibaraki, Japan This book series cover a variety of topics in respiratory diseases, with each volume providing an overview of the current state of knowledge, recent discoveries and future prospects for each disease. In each chapter the editors pose critical questions, which are often unresolved clinical issues. These are then discussed by the authors, providing insights and suggestions as to which developments need to be addressed. The series offers new information, which will inspire innovative ideas to further develop respiratory medicine. This collection of monographs is aimed at benefiting patients across the globe suffering from respiratory disease. Edited by established authorities in the field and written by pioneering experts, this book series will be valuable to those researchers and physicians working in respiratory medicine. The series is aimed at a broad readership, and the books will also be a valuable resource for radiologists, emergency medicine physicians, pathologists, pharmacologists and basic research scientists. More information about this series at http://www.springer.com/series/15152 Masayuki Hanaoka • Hiroyuki Nakamura Kazutetsu Aoshiba Editors Drug-Induced Lung Injury Editors Masayuki Hanaoka Hiroyuki Nakamura First Department of Medicine Ibaraki Medical Center Shinshu University School of Medicine Tokyo Medical University Matsumoto, Nagano, Japan Ibaraki, Japan Kazutetsu Aoshiba Ibaraki Medical Center Tokyo Medical University Ibaraki, Japan ISSN 2509-5552 ISSN 2509-5560 (electronic) Respiratory Disease Series: Diagnostic Tools and Disease Managements ISBN 978-981-10-4465-6 ISBN 978-981-10-4466-3 (eBook) https://doi.org/10.1007/978-981-10-4466-3 Library of Congress Control Number: 2017955815 © Springer Nature Singapore Pte Ltd. 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore Preface Why is the disorder of drug-induced lung injury important currently? Drug-induced lung injury refers to drug-related respiratory disorder that occurs during administration of drugs in the treatment of original diseases. The reasons for which drug-induced lung injury is noted and considered important are summarized as below: 1. The number of clinical reports about drug-induced lung injury is increasing. In recent years, new drugs, such as biological products, molecular-targeted drugs, and immune checkpoint inhibitors, are presented successively on phar- macy markets. Consequently, the cases of occurrence of drug-induced lung injury are increasingly reported. 2. According to studies worldwide, the incidence of drug-induced lung injury is different among human ethnicities. For example, the incidences of drug-induced lung injury due to bleomycin or gefitinib through the mechanism of cytotoxicity are a high trend in the Japanese population. 3. Cases may manifest clinically severe with diffuse alveolar damage (DAD). The drug-induced lung injury with DAD responds insufficiently to treatment bringing about poor prognosis. 4. The drug-induced lung injury shows a diversity of clinical types. For example, the drug-induced lung injury due to methotrexate may manifest different clinical types depending on cases. 5. The new pathological state of drug-induced lung injury is identified recently. For example, the incidence of interstitial pneumonia due to mTOR inhibitor is relatively high. However, if the disorder is clinically mild, the administration of mTOR inhibitor can be continued or readministered after a while of withdrawal of mTOR inhibitor. 6. The drug-induced lung injury is involved with various medical fields. Drug-induced lung injury is an unavoidable circumstance for all medical doctors who do the administration of drugs to their patients in disease treatment. v vi Preface In the diagnosis of drug-induced lung injury, it is important to always keep in mind the principle that all drugs may cause lung injury, giving a suspicious impres- sion of drug-induced lung injury. Clinicians have to differentiate the abnormal lung shadows appearing on the chest images during drug administration. However, it is often quite difficult to distinguish it from other diseases, such as the deteriora- tion of original lung lesions or infectious diseases, because of the diversity and non- specificity of clinical types of drug-induced lung injury. Japan is in leading positions on many of the research fields regarding clinical epidemiology, serum markers, and CT diagnostic images of drug-induced lung injury in the world. The authors of this book are the researchers and clinicians who work in the first line of defense against drug-induced lung injury in Japan. Specifically, it’s not an exaggeration to say that this book is a culmination of knowl- edge of what has been achieved on drug-induced lung injury. Needless to say, this book will be very helpful for clinicians in their daily medical practice; at the same time, it will serve as a compass in the basic and clinical researches for elucidation of the unknowns of drug-induced lung injury. I hope this book will be fully and widely used by many doctors and researchers for their aims. Matsumoto, Japan Masayuki Hanaoka Ibaraki, Japan Hiroyuki Nakamura Ibaraki, Japan Kazutetsu Aoshiba Contents Part I Definition, Pathogenesis, and Epidemiology 1 Definition and Pathogenesis of Drug-Induced Lung Injury: What Is DLI? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Hidetoshi Nakamura and Minoru Kanazawa 2 Epidemiology and Risk Factors of Drug- Induced Lung Disease: What Are the Prevalence and Risk Factors of DILD? . . . . . . . . . . . . . . 13 Tomohiro Handa, Atsushi Yonezawa, and Arata Azuma 3 Clinical Characteristics of DLI: What Are the Clinical Features of DLI? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Atsuhito Ushiki and Masayuki Hanaoka Part II Diagnosis 4 Diagnostic Approach for DLI: How is DLI Diagnosed? . . . . . . . . . . . . 37 Shu Hashimoto, Mari Hikichi, Mai Takahashi, and Yasuhiro Gon 5 Blood Tests for the Diagnosis and/or Management of DLI: What Are the Clinical Significances of KL-6, SP-A, SP-D, and DLST in DLI? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 Yasushi Horimasu and Noboru Hattori 6 Imaging Features of Drug-Induced Interstitial Lung Disease: How HRCT of DLI Is Interpreted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59 Fumikazu Sakai 7 Pathology of DLI: What Is the Pathological Significance of DLI? . . . . 83 Yasuhiro Terasaki and Yuh Fukuda 8 Differential Diagnoses of DLI: What Are the Differential Diagnoses of DLI? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103 Akihito Yokoyama vii viii Contents Part III Treatment 9 Therapeutic Strategies for DLI: How Should DLI Be Treated? . . . . . 115 Sakae Homma Part IV Drugs Causing DLI 10 DLI Induced by Nonmolecular Target Antineoplastic Drugs: What Are the Characteristics of DLI in Nonmolecular Target Antineoplastic Drugs? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129 Yasuo Saijo 11 DLI Induced by Molecular Target Antineoplastic Drug: What Are the Characteristics of DLI in Molecular Target Antineoplastic Drugs?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139 Nobuyuki Koyama 12 DLI Caused by Disease-Modifying Antirheumatic Drugs: What Are the Characteristics of DLI by Disease- Modifying Antirheumatic Drugs? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165 Hideto Kameda 13 DLI Induced by Herbal Medicine: What Are the Characteristics of DLI due to Herbal Medicines? . . . . . . . . . . . . . . . . . 177 Mitsuhiro Abe, Kenji Tsushima, and Koichiro Tatsumi 14 DLI Induced by Antiarrhythmic Drug and Antimicrobial Drug: What Are the Characteristics of DLI in Antiarrhythmic Drugs and Antimicrobial Drugs? . . . . . . . . . . . . . . 201 Fumio Sakamaki Part I Definition, Pathogenesis, and Epidemiology
The list of books you might like
